

**ASX Announcement**

(ASX:RSH)

Date: 30 July 2019

RESPIRI LIMITED | \$3.4 million SHARE PLACEMENT

Respiri Limited (ASX:RSH) (Respiri or Company) is pleased to announce it has successfully conducted a \$3.4 million capital raising via a private placement to sophisticated and professional investors (Placement). The Placement price is 10.0 cents per fully paid ordinary share (Share) in the capital of the Company.

The fund raising has had broad support from a number of Respiri's long-term investors and was underpinned by leading family offices including the Smedley Family Office. The Placement also includes \$100,000 from the directors of the Company (subject to shareholder approval at Respiri's AGM).

The Lead Manager for the fund raising was Fawkner Capital.

Successful capital raising with new valued shareholders

There is an aggregate of 34,000,000 Shares issued under the Placement. Post settlement of the Placement, the Company's capital fully paid ordinary share structure will be 559,883,098 fully paid ordinary shares.

The Shares will be issued in connection with the Placement using the Company's Listing rule 7.1 and 7.1A capacity as follows:

- LR7.1 – 24,000,000
- LR7.1A – 10,000,000

Commenting on the Placement, Chief Executive Officer Mario Gattino said:

“A key focus of the Company's activities for the coming months is capitalising on the early interest and emerging demand from India. This new equity will allow us to increase our focus on first sales to India, and to complete our clinical studies, in anticipation of CE mark approval.”

Further detail on the proposed use of Placement proceeds

The Company intends to use the proceeds from the Placement for the following (but without limitation):

1. Payments to key suppliers – Grey Innovation (technology), Two Bulls (software and app development) and SRX (manufacturer).
2. Establish manufacturing and supply chain processes to meet initial orders and demand from India.
3. Corporate overhead expenses
4. Working capital.
5. Ongoing Clinical studies costs and building clinical evidence for wheezo
6. Market development expenses – India and Australia.
7. Review and strengthen Respiri's multi-faceted Intellectual Property (IP) with anticipation of filing new patents / IP, trademarks & copyright across all major geographies
8. Expenses of the Offer

**Key Placement Details:**

- Placement Issue Price: 10.0 cents per Share. The Issue Price is at a:
 - 17% discount to the closing share price of 12.0 cents on 24 July 2019; and
 - 5% discount to the 15-day VWAP share price of 10.5 cents up to and including 24 July 2019.
- Number of Securities: 34,000,000 fully paid ordinary shares.
- Proceeds of the Placement: \$3.4 million (before the costs and fees associated with the Placement)
- Expected Placement settlement date: 8 August 2019

Mario Gattino

CEO and Director
+61 3 9653 9160

-END-

About Respiri Limited (ASX:RSH)

Respiri's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

respiri.co